Attractively Priced Originals: EU Pharmaceuticals
In 1982, Arrowedge Ltd was founded as a pioneer in the market for parallel imports of low-cost EU medicinal products. Our business model lets us combine profitable growth with a measurable reduction in health care costs.
The prices for identical original products vary across Europe due to the different health care systems in place. In 2014, health care costs in Germany alone were cut by some 240 million euros thanks to parallel imports. Furthermore, in Germany a further 3 billion euros in savings are the indirect result of competitive pressure brought about by trade with EU pharmaceuticals – in particular high-priced products protected by patents. Imports offer the sole method of controlling pricing and competition and thus keeping the costs of medicinal products down. Pharmacies and patients are unable to use lower-cost generic alternatives. Around 80 percent of all EU medicinal products sold by Arrowedge are patented.
By importing these products at more attractive price, we help pharmacies to make indirect cost savings as a result of purchasing their products from pharmaceutical wholesalers or attractive purchasing conditions when ordering directly.